FUSION PROTEIN PREPARATION COMPRISING IL-2 AND CD80 PROTEINS
The present invention relates to a pharmaceutical formulation having improved stability of a fusion protein dimer containing modified IL-2 and CD80 proteins. The fusion protein dimer containing IL-2 and CD80 proteins can not only activate immune cells by IL-2, but also effectively regulate Treg cell...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; kor |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | NAM, Su Youn JANG, Myoung Ho OH, Young Min KWON, Soontak CHO, Young-Gyu LIM, Heonchang |
| description | The present invention relates to a pharmaceutical formulation having improved stability of a fusion protein dimer containing modified IL-2 and CD80 proteins. The fusion protein dimer containing IL-2 and CD80 proteins can not only activate immune cells by IL-2, but also effectively regulate Treg cells by CD80. The application of the formulation according to the present invention to the fusion protein dimer containing IL-2 and CD80 proteins not only can significantly improve the stability of the fusion protein dimer, but can also be used as a liquid formulation, leading to high commercial usability of the fusion protein dimer.
La présente invention concerne une formulation pharmaceutique ayant une stabilité améliorée d'un dimère de protéine de fusion contenant des protéines IL-2 et CD80 modifiées. Le dimère de protéine de fusion contenant des protéines IL-2 et CD80 peut non seulement activer des cellules immunitaires par IL -2, mais également réguler efficacement des cellules Treg par CD80. L'application de la formulation selon la présente invention au dimère de protéine de fusion contenant des Protéines IL-2 et CD80 permet non seulement d'améliorer significativement la stabilité du dimère de protéine de fusion, mais peut également être utilisée en tant que formulation liquide, ce qui conduit à une grande facilité d'utilisation commerciale du dimère de protéine de fusion.
본 발명은 변형된 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체의 안정성을 향상시킨 약제학적 제형에 관한 것이다. IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체는 IL-2에 의해 면역세포를 활성화시킬 수 있을 뿐 아니라, CD80에 의해 Treg 세포를 효과적으로 조절할 수 있다. 본 발명에 따른 제형을 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체에 적용할 경우 상기 융합단백질 이량체의 안정성이 현저히 증가할 뿐 아니라, 액상 제형으로 이용 가능하므로 융합단백질 이량체의 상업적 활용성을 높일 수 있다. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2021187897A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2021187897A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2021187897A13</originalsourceid><addsrcrecordid>eNrjZLBxCw329PdTCAjyD3H1BNGuAY5BjiEgMWd_34Agz2BPP3cFTx9dIwVHPxcFZxcLA5jiYB4G1rTEnOJUXijNzaDs5hri7KGbWpAfn1pckJicmpdaEh_ub2RgZGhoYW5hae5oaEycKgCl3yps</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FUSION PROTEIN PREPARATION COMPRISING IL-2 AND CD80 PROTEINS</title><source>esp@cenet</source><creator>NAM, Su Youn ; JANG, Myoung Ho ; OH, Young Min ; KWON, Soontak ; CHO, Young-Gyu ; LIM, Heonchang</creator><creatorcontrib>NAM, Su Youn ; JANG, Myoung Ho ; OH, Young Min ; KWON, Soontak ; CHO, Young-Gyu ; LIM, Heonchang</creatorcontrib><description>The present invention relates to a pharmaceutical formulation having improved stability of a fusion protein dimer containing modified IL-2 and CD80 proteins. The fusion protein dimer containing IL-2 and CD80 proteins can not only activate immune cells by IL-2, but also effectively regulate Treg cells by CD80. The application of the formulation according to the present invention to the fusion protein dimer containing IL-2 and CD80 proteins not only can significantly improve the stability of the fusion protein dimer, but can also be used as a liquid formulation, leading to high commercial usability of the fusion protein dimer.
La présente invention concerne une formulation pharmaceutique ayant une stabilité améliorée d'un dimère de protéine de fusion contenant des protéines IL-2 et CD80 modifiées. Le dimère de protéine de fusion contenant des protéines IL-2 et CD80 peut non seulement activer des cellules immunitaires par IL -2, mais également réguler efficacement des cellules Treg par CD80. L'application de la formulation selon la présente invention au dimère de protéine de fusion contenant des Protéines IL-2 et CD80 permet non seulement d'améliorer significativement la stabilité du dimère de protéine de fusion, mais peut également être utilisée en tant que formulation liquide, ce qui conduit à une grande facilité d'utilisation commerciale du dimère de protéine de fusion.
본 발명은 변형된 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체의 안정성을 향상시킨 약제학적 제형에 관한 것이다. IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체는 IL-2에 의해 면역세포를 활성화시킬 수 있을 뿐 아니라, CD80에 의해 Treg 세포를 효과적으로 조절할 수 있다. 본 발명에 따른 제형을 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체에 적용할 경우 상기 융합단백질 이량체의 안정성이 현저히 증가할 뿐 아니라, 액상 제형으로 이용 가능하므로 융합단백질 이량체의 상업적 활용성을 높일 수 있다.</description><language>eng ; fre ; kor</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210923&DB=EPODOC&CC=WO&NR=2021187897A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210923&DB=EPODOC&CC=WO&NR=2021187897A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>NAM, Su Youn</creatorcontrib><creatorcontrib>JANG, Myoung Ho</creatorcontrib><creatorcontrib>OH, Young Min</creatorcontrib><creatorcontrib>KWON, Soontak</creatorcontrib><creatorcontrib>CHO, Young-Gyu</creatorcontrib><creatorcontrib>LIM, Heonchang</creatorcontrib><title>FUSION PROTEIN PREPARATION COMPRISING IL-2 AND CD80 PROTEINS</title><description>The present invention relates to a pharmaceutical formulation having improved stability of a fusion protein dimer containing modified IL-2 and CD80 proteins. The fusion protein dimer containing IL-2 and CD80 proteins can not only activate immune cells by IL-2, but also effectively regulate Treg cells by CD80. The application of the formulation according to the present invention to the fusion protein dimer containing IL-2 and CD80 proteins not only can significantly improve the stability of the fusion protein dimer, but can also be used as a liquid formulation, leading to high commercial usability of the fusion protein dimer.
La présente invention concerne une formulation pharmaceutique ayant une stabilité améliorée d'un dimère de protéine de fusion contenant des protéines IL-2 et CD80 modifiées. Le dimère de protéine de fusion contenant des protéines IL-2 et CD80 peut non seulement activer des cellules immunitaires par IL -2, mais également réguler efficacement des cellules Treg par CD80. L'application de la formulation selon la présente invention au dimère de protéine de fusion contenant des Protéines IL-2 et CD80 permet non seulement d'améliorer significativement la stabilité du dimère de protéine de fusion, mais peut également être utilisée en tant que formulation liquide, ce qui conduit à une grande facilité d'utilisation commerciale du dimère de protéine de fusion.
본 발명은 변형된 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체의 안정성을 향상시킨 약제학적 제형에 관한 것이다. IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체는 IL-2에 의해 면역세포를 활성화시킬 수 있을 뿐 아니라, CD80에 의해 Treg 세포를 효과적으로 조절할 수 있다. 본 발명에 따른 제형을 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체에 적용할 경우 상기 융합단백질 이량체의 안정성이 현저히 증가할 뿐 아니라, 액상 제형으로 이용 가능하므로 융합단백질 이량체의 상업적 활용성을 높일 수 있다.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLBxCw329PdTCAjyD3H1BNGuAY5BjiEgMWd_34Agz2BPP3cFTx9dIwVHPxcFZxcLA5jiYB4G1rTEnOJUXijNzaDs5hri7KGbWpAfn1pckJicmpdaEh_ub2RgZGhoYW5hae5oaEycKgCl3yps</recordid><startdate>20210923</startdate><enddate>20210923</enddate><creator>NAM, Su Youn</creator><creator>JANG, Myoung Ho</creator><creator>OH, Young Min</creator><creator>KWON, Soontak</creator><creator>CHO, Young-Gyu</creator><creator>LIM, Heonchang</creator><scope>EVB</scope></search><sort><creationdate>20210923</creationdate><title>FUSION PROTEIN PREPARATION COMPRISING IL-2 AND CD80 PROTEINS</title><author>NAM, Su Youn ; JANG, Myoung Ho ; OH, Young Min ; KWON, Soontak ; CHO, Young-Gyu ; LIM, Heonchang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2021187897A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; kor</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>NAM, Su Youn</creatorcontrib><creatorcontrib>JANG, Myoung Ho</creatorcontrib><creatorcontrib>OH, Young Min</creatorcontrib><creatorcontrib>KWON, Soontak</creatorcontrib><creatorcontrib>CHO, Young-Gyu</creatorcontrib><creatorcontrib>LIM, Heonchang</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>NAM, Su Youn</au><au>JANG, Myoung Ho</au><au>OH, Young Min</au><au>KWON, Soontak</au><au>CHO, Young-Gyu</au><au>LIM, Heonchang</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FUSION PROTEIN PREPARATION COMPRISING IL-2 AND CD80 PROTEINS</title><date>2021-09-23</date><risdate>2021</risdate><abstract>The present invention relates to a pharmaceutical formulation having improved stability of a fusion protein dimer containing modified IL-2 and CD80 proteins. The fusion protein dimer containing IL-2 and CD80 proteins can not only activate immune cells by IL-2, but also effectively regulate Treg cells by CD80. The application of the formulation according to the present invention to the fusion protein dimer containing IL-2 and CD80 proteins not only can significantly improve the stability of the fusion protein dimer, but can also be used as a liquid formulation, leading to high commercial usability of the fusion protein dimer.
La présente invention concerne une formulation pharmaceutique ayant une stabilité améliorée d'un dimère de protéine de fusion contenant des protéines IL-2 et CD80 modifiées. Le dimère de protéine de fusion contenant des protéines IL-2 et CD80 peut non seulement activer des cellules immunitaires par IL -2, mais également réguler efficacement des cellules Treg par CD80. L'application de la formulation selon la présente invention au dimère de protéine de fusion contenant des Protéines IL-2 et CD80 permet non seulement d'améliorer significativement la stabilité du dimère de protéine de fusion, mais peut également être utilisée en tant que formulation liquide, ce qui conduit à une grande facilité d'utilisation commerciale du dimère de protéine de fusion.
본 발명은 변형된 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체의 안정성을 향상시킨 약제학적 제형에 관한 것이다. IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체는 IL-2에 의해 면역세포를 활성화시킬 수 있을 뿐 아니라, CD80에 의해 Treg 세포를 효과적으로 조절할 수 있다. 본 발명에 따른 제형을 IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체에 적용할 경우 상기 융합단백질 이량체의 안정성이 현저히 증가할 뿐 아니라, 액상 제형으로 이용 가능하므로 융합단백질 이량체의 상업적 활용성을 높일 수 있다.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; kor |
| recordid | cdi_epo_espacenet_WO2021187897A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | FUSION PROTEIN PREPARATION COMPRISING IL-2 AND CD80 PROTEINS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A39%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=NAM,%20Su%20Youn&rft.date=2021-09-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2021187897A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |